Crossmark

Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice

Crossref DOI link: https://doi.org/10.1007/s11523-019-00688-8

Published Online: 2019-11-21

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Czarnecka, Anna M. https://orcid.org/0000-0002-2107-3810
Teterycz, Paweł

Mariuk-Jarema, Anna

Lugowska, Iwona

Rogala, Pawel

Dudzisz-Sledz, Monika

Switaj, Tomasz

Rutkowski, Piotr
License Information

Text and Data Mining valid from 2019-11-21

Version of Record valid from 2019-11-21
More Information

Article History

First Online: 21 November 2019

Compliance with Ethical Standards

:

: Data analysis and manuscript preparation were supported with Maria Sklodowska-Curie Institute-Oncology Center statutory founding.

: Anna M. Czarnecka, Tomasz Switaj, Monika Dudzisz-Sledz, Iwona Lugowska, Piotr Rutkowski, and Pawel Rogala received support for travel and payment for lectures and consulting fees or honorarium form BMS, MSD, Roche, and Novartis. Piotr Rutkowski received grants from BMS and Novartis; consulting honoraria from BMS, MSD, Roche and Novartis; travel support from Pierre Fabre and Orphan drugs; advisory board honoraria from Novartis, Amgen, Blueprint Medicines, Pierre Fabre, BMS and MSD; and payment for lectures from Pfizer and Eli Lilly. Paweł Teterycz and Anna Mariuk-Jarema declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.

Document is current

Any future updates will be listed below